Reported 2 days ago
Gilead Sciences, Inc. (NASDAQ:GILD) will present over 20 research abstracts, including key Phase 3 results from the ASCENT-04 trial, at the upcoming 2025 ASCO Annual Meeting and EHA Congress. The studies will address various cancers such as breast cancer and glioblastoma, highlighting advancements in therapies like Trodelvy® and novel CAR T-cell treatments. Gilead continues to demonstrate a strong financial performance, with a consistent dividend payout, despite the rising focus on AI stock investments.
Source: YAHOO